Private company

CinCor Pharma, Inc.

American pharmaceutical preparations company based in Cincinnati1

In its 2022 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. We are conducting multiple Phase 2 clinical trials using CIN-107 in differing populations of patients, all of whom are hypertensive.”40

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inDE2
  • Business address230 Third Ave., 6Th Floor, Waltham, Ma 024512
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$42.5M in 2021+101% since 2020
-$60.0M-$40.0M-$20.0M02020: -$21.1M-$21.1M20202021: -$42.5M-$42.5M2021+101%
Net income3-$50.4M in 2021+126% since 2020
-$60.0M-$40.0M-$20.0M02020: -$22.3M-$22.3M20202021: -$50.4M-$50.4M2021+126%
Fiscal year2019202020212022
Research and development$19.2M3$21.5M3
Operating expenses$42.5M3
Operating income-$21.1M3-$42.5M3
Net income-$22.3M3-$50.4M3

Compare CinCor Pharma, Inc. with another company

Corporate structure

CinCor Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CinCor Pharma, Inc.

  • Sofinnova Capital IX Filed SC 13D/A on CinCor Pharma, Inc., latest Mar 3, 2023 (2 filings since Feb 13, 2023)
  • Sofinnova Venture Partners X, L.P. Filed SC 13D/A on CinCor Pharma, Inc., latest Mar 1, 2023 (3 filings since Jan 21, 2022)
  • 5AM Ventures VI, L.P. Filed SC 13D/A on CinCor Pharma, Inc., latest Feb 28, 2023 (3 filings since Jan 21, 2022)
  • GENERAL ATLANTIC, L.P. Filed SC 13D/A on CinCor Pharma, Inc., latest Feb 28, 2023 (3 filings since Jan 21, 2022)
  • PERCEPTIVE ADVISORS LLC Filed SC 13G on CinCor Pharma, Inc., latest Feb 14, 2023
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on CinCor Pharma, Inc., latest Feb 9, 2023 (2 filings since Jan 21, 2022)
  • venBio Global Strategic Fund III, L.P. Filed SC 13G/A on CinCor Pharma, Inc., latest Sep 26, 2022 (2 filings since Jan 11, 2022)
  • CinRx Pharma, LLC Filed SC 13G on CinCor Pharma, Inc., latest Jan 11, 2022
  • CinCor Pharma, Inc. Waltham, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CinCor Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Real estate and locations

ItemLatestA year beforeChange
Area of real estate5,400 sq ft3 Feb 24, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$136.6M3 Dec 31, 2021$26.1M3 Dec 31, 2020+423.8%

Leadership

Who has led CinCor Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Garidel Marc De2022–2023

Chief financial officer

  1. Mary Theresa Coelho2022
  2. Michael Wayne Kalb2022–2023

Chief operating officer

  1. Catherine Pearce2022–2023
2025
Board members and other officers (9)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMarc de Garidel named Oct 12, 202118

Timeline

  1. Feb 24, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights19
  2. Feb 21, 20238-K Regulation FD disclosure20
  3. Jan 9, 20238-K Entered a material agreement; Executive or director change; Other events21
  4. Nov 28, 20228-K Regulation FD disclosure22
  5. Nov 8, 20228-K Regulation FD disclosure23
  6. Nov 7, 20228-K Executive or director change; Regulation FD disclosure24
  7. Nov 4, 20228-K Results of operations25
  8. Nov 3, 20228-K Results of operations26
  9. Aug 11, 20228-K Other events27
  10. Aug 8, 20228-K Regulation FD disclosure28
  11. Aug 8, 20228-K Results of operations29
  12. May 10, 20228-K Results of operations30
  13. Jan 6, 2022New chief executive Garidel Marc De becomes CEO6

Calendar

When it reported results

  1. Nov 4, 2022Reported quarterly or annual results25
  2. Nov 3, 2022Reported quarterly or annual results26
  3. Aug 8, 2022Reported quarterly or annual results29
  4. May 10, 2022Reported quarterly or annual results30
  5. Mar 22, 2022Reported quarterly or annual results31

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

134 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 15 major events, 60 insider forms, 17 large holders, 1 private raises, 37 other. The latest 20:

  1. Mar 6, 202315-12G EDGAR
  2. Mar 3, 2023SC 13D/A EDGAR
  3. Mar 1, 2023SC 13D/A EDGAR
  4. Feb 28, 20234 FORM 4 SUBMISSION EDGAR
  5. Feb 28, 2023SC 13D/A EDGAR
  6. Feb 28, 2023SC 13D/A AMENDMENT NO. 2 EDGAR
  7. Feb 27, 20234 FORM 4 SUBMISSION EDGAR
  8. Feb 27, 20234 FORM 4 SUBMISSION EDGAR
  9. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  10. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  11. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  12. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  13. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  14. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  15. Feb 24, 20234 FORM 4 SUBMISSION EDGAR
  16. Feb 24, 2023S-8 POS EDGAR
  17. Feb 24, 20238-K EDGAR
  18. Feb 24, 2023SC 14D9/A EDGAR
  19. Feb 23, 2023SC 14D9/A EDGAR
  20. Feb 21, 20238-K EDGAR

The 134 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

18 open-market trades by officers, directors and large owners since October 2021: 16 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 28, 2022HEALY JAMESDirectorSale6,000$14.32$85.9KForm 4
Aug 15, 20225AM Partners VI, LLC10% ownerBuy600,000$30.00$18.0MForm 4
Aug 15, 2022Sofinnova Partners SAS10% ownerBuy133,333$30.00$4.0MForm 4
Aug 11, 2022Sofinnova Management X, L.L.C.10% ownerBuy500,000$30.00$15.0MForm 4
Aug 11, 2022HEALY JAMESDirectorBuy506,000$30.00$15.2MForm 4
Aug 11, 2022GENERAL ATLANTIC GENPAR (BERMUDA), L.P.10% ownerBuy83,000$30.00$2.5MForm 4
Aug 11, 2022GAP COINVESTMENTS III, LLC10% ownerBuy83,000$30.00$2.5MForm 4
Jun 10, 2022Freeman MasonChief Medical OfficerSale6$15.21$91Form 4
Jan 11, 2022PARMAR KUSH10% ownerBuy470,000$16.00$7.5MForm 4
Jan 11, 2022Sofinnova Venture Partners X, L.P.10% ownerBuy325,000$16.00$5.2MForm 4
Jan 11, 2022Sofinnova Capital IX10% ownerBuy220,000$16.00$3.5MForm 4
Jan 11, 2022HEALY JAMESDirectorBuy325,000$16.00$5.2MForm 4
Jan 11, 2022Pearce CatherineChief Operating OfficerBuy2,250$16.00$36.0KForm 4
Jan 11, 2022Freeman MasonChief Medical OfficerBuy2,600$16.00$41.6KForm 4
Jan 11, 2022de Garidel MarcChief Executive OfficerBuy12,500$16.00$200.0KForm 4
Jan 11, 2022Coelho Mary TheresaEVP CFO & Chief BD OfficerBuy100$16.00$1.6KForm 4
Jan 11, 2022GENERAL ATLANTIC GENPAR (BERMUDA), L.P.10% ownerBuy1,700,000$16.00$27.2MForm 4
Jan 11, 2022GAP COINVESTMENTS III, LLC10% ownerBuy1,700,000$16.00$27.2MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 22, 2021Raised $142.9 million in a private offering of equity Form D: 22 investors so far Form D

SEC filer profile

How CinCor Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCinCor Pharma, Inc.1
  • CIK0001868734
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address230 Third Ave., 6Th Floor, Waltham, MA 024511
  • Phone84453118341
  • Shares outstanding43,764,323 as of Nov 3, 20225
  • Public float$0 as of Jun 30, 20213
  • On EDGAR sinceAug 27, 20211
  • Filings141 in all: 4 (40), 3 (18), 8-K (14), SC 13D/A (6), SC 13G (5), SC 14D9/A (5), CORRESP (4), SC 13D (4)1
    All 36 form types

    10-Q (3), SC TO-T/A (3), UPLOAD (3), 4/A (2), 424B4 (2), DRS (2), DRS/A (2), DRSLTR (2), EFFECT (2), S-1 (2), S-1/A (2), S-1MEF (2), SC 13G/A (2), SEC STAFF LETTER (2), 10-K (1), 15-12G (1), 25-NSE (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), POS EX (1), S-8 (1), S-8 POS (1), SC 14D9 (1), SC TO-C (1), SC TO-T (1), SC14D9C (1)

  • Latest filingsAnnual report (10-K) Mar 22, 2022
    Quarterly report (10-Q) Nov 3, 2022
    Latest 8-K (8-K) Feb 24, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40